Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure

European Heart Journal

Volumn 34, Issue 36, 2013, Pages

  Vogel, Britta ^a,b   Keller, Andreas ^c,d   Frese, Karen S ^a,b   Leidinger, Petra ^d   Sedaghat Hamedani, Farbod ^a   Kayvanpour, Elham ^a   Kloos, Wanda ^a   Backe, Christina ^d   Thanaraj, Ann ^a   Brefort, Thomas ^c   Beier, Markus ^c   Hardt, Stefan ^a   Meese, Eckart ^d   Katus, Hugo A ^a,b   Meder, Benjamin ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c Biomarker Discovery Center Heidelberg   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

Biomarker; HF REF; miRNA; Non ischaemic heart failure

Indexed keywords

BIOLOGICAL MARKER; CD15 ANTIGEN; CD3 ANTIGEN; MICRORNA; MICRORNA 122; MICRORNA 1228; MICRORNA 1231; MICRORNA 200B; MICRORNA 519E; MICRORNA 558; MICRORNA 622; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTOLIC HEART FAILURE; SYSTOLIC HEART FAILURE WITH REDUCED EJECTION FRACTION;

BIOMARKER; HF-REF; MIRNA; NON-ISCHAEMIC HEART FAILURE;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HEART FAILURE, SYSTOLIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84884851360     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht256     Document Type: Article

References (37)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the D, Treatment of A, Chronic Heart Failure of the European Society of C, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, Guidelines ESCCfP. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
2. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8: 1308-1339.
3. Haas J, Frese KS, Park YJ, Keller A, Vogel B, Lindroth AM, Weichenhan D, Franke J, Fischer S, Bauer A, Marquart S, Sedaghat-Hamedani F, Kayvanpour E, Kohler D, Wolf NM, Hassel S, Nietsch R, Wieland T, Ehlermann P, Schultz JH, Dosch A, Mereles D, Hardt S, Backs J, Hoheisel JD, Plass C, Katus HA, Meder B. Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol Med 2013; 5: 413-429.
4. Backes C, Meese E, Lenhof HP, Keller A. A dictionary on miRNAs and their putative target pathways. Nucleic Acids Res 2010; 38: 4476-4486.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
6. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, Rojas M, Hammond SM, Schneider MD, Selzman CH, Meissner G, Patterson C, Hannon GJ, Wang DZ. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA 2008; 105: 2111-2116.
7. Zhang X, Azhar G, Wei JY. The expression of miRNA and miRNA clusters in the aging heart. PLoS One 2012; 7: e34688.
8. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM. MiR423-5p as a circulating biomarker for heart failure. Circ Res 106: 1035-1039.
9. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH, Dorn LE, Watson MA, Margulies KB, Dorn GW II. Reciprocal regulation of myocardial miRNAs and messenger RNA in human cardiomyopathy and reversal of the miRNA signature by biomechanical support. Circulation 2009; 119: 1263-1271.
10. Naga Prasad SV, Duan ZH, Gupta MK, Surampudi VS, Volinia S, Calin GA, Liu CG, Kotwal A, Moravec CS, Starling RC, Perez DM, Sen S, Wu Q, Plow EF, Croce CM, Karnik S. UniquemiRNAprofile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem 2009; 284: 27487-27499.
11. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, Werner J, Hackert T, Ruprecht K, Huwer H, Huebers J, Jacobs G, Rosenstiel P, Dommisch H, Schaefer A, Muller-Quernheim J, Wullich B, Keck B, Graf N, Reichrath J, Vogel B, Nebel A, Jager SU, Staehler P, Amarantos I, Boisguerin V, Staehler C, Beier M, Scheffler M, Buchler MW, Wischhusen J, Haeusler SF, Dietl J, Hofmann S, Lenhof HP, Schreiber S, Katus HA, RottbauerW, Meder B, Hoheisel JD, Franke A, Meese E. Toward the blood-borne miRNome of human diseases. Nat Methods 2011; 8: 841-843.
12. Satoh M, Minami Y, Takahashi Y, Tabuchi T, NakamuraM.A cellular miRNA, let-7i, is a novel biomarker for clinical outcome in patients with dilated cardiomyopathy. J Card Fail 2011; 17: 923-929.
13. Belevych AE, Sansom SE, Terentyeva R, Ho HT, Nishijima Y, Martin MM, Jindal HK, Rochira JA, Kunitomo Y, Abdellatif M, Carnes CA, Elton TS, Gyorke S, Terentyev D. MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One 2011; 6: e28324.
14. Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of miRNAs in patients with heart failure. Eur J Heart Fail 2012; 14: 147-154.
15. Vogel B, Keller A, Frese KS, KloosW, Kayvanpour E, Sedaghat-Hamedani F, Hassel S, Marquart S, Beier M, Giannitis E, Hardt S, Katus HA, Meder B. Refining diagnostic miRNA signatures by whole-miRNome kinetic analysis in acute myocardial infarction. Clin Chem 2013; 59: 410-418.
16. Lainscak M, Anker MS, von Haehling S, Anker SD. Biomarkers for chronic heart failure: diagnostic, prognostic, and therapeutic challenges. Herz 2009; 34: 589-593.
17. Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP, Meese E. miRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer 2009; 9: 353.
18. Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M, Lenhof HP, Ruprecht K, Meese E. Multiple sclerosis: miRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS ONE 2009; 4: e7440.
19. Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Just S, Borries A, Rudloff J, Leidinger P, Meese E, Katus HA, RottbauerW. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 106: 13-23.
20. Song J, Bai Z, HanW, Zhang J, Meng H, Bi J, Ma X, Han S, Zhang Z. Identification of suitable reference genes for qPCR analysis of serum miRNA in gastric cancer patients. Dig Dis Sci 2012; 57: 897-904.
21. Cortes C, Vapnik V. Support-Vector Networks. Machine Learning 1995; 273-297.
22. Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res 110: 126-144.
23. Pfister R, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Differential white blood cell count and incident heart failure in men and women in the EPIC-Norfolk study. Eur Heart J 2012; 33: 523-530.
24. Korantzopoulos P, Vlachou C, Kotsia A, Kalantzi K, Barbouti A, Galaris D, Goudevenos JA. Leukocyte labile iron pool in patients with systolic heart failure. Hellenic J Cardiol 2012; 53: 95-100.
25. Uthamalingam S, Patvardhan EA, Subramanian S, Ahmed W, Martin W, Daley M, Capodilupo R. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol 2011; 107: 433-438.
26. Tijsen AJ, Pinto YM, Creemers EE. Non-cardiomyocyte miRNAs in heart failure. Cardiovasc Res 2012; 93: 573-582.
27. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, WangW, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Zen K, Zhang CY. Characterization of miRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
28. Fenoglio C, Ridolfi E, Galimberti D, Scarpini E. MicroRNAs as active players in the pathogenesis of multiple sclerosis. Int J Mol Sci 2012; 13: 13227-13239.
29. Andersson P, Gidlof O, Braun OO, Gotberg M, van der Pals J, Olde B, Erlinge D. Plasma levels of liver-specific miR-122 is massively increased in a porcine cardiogenic shock model and attenuated by hypothermia. Shock 37: 234-238.
30. Sivakumar R, Wellsted D, Parker K, Lynch M, Ghosh P, Khan SA. Utility ofNterminal pro brain natriuretic peptide in elderly patients. Postgrad Med J 2006; 82: 220-223.
31. Koschack J, Scherer M, Luers C, Kochen MM, Wetzel D, Kleta S, Pouwels C, Wachter R, Herrmann-Lingen C, Pieske B, Binder L. Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care. BMC Fam Pract 2008; 9: 14.
32. Muders F, Kromer EP, GrieseDP, Pfeifer M, HenseHW, Riegger GA, Elsner D. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997; 134: 442-449.
33. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-1353.
34. Ellis KL, Cameron VA, TroughtonRW, Frampton CM, Ellmers LJ, Richards AM. Circulating miRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail; doi: 10.1093/eurjhf/hft078. Published online ahead of print 21 May 2013.
35. Vorwerk S, Ganter K, Cheng Y, Hoheisel J, Stahler PF, Beier M. Microfluidic-based enzymatic on-chip labeling of miRNAs. N Biotechnol 2008; 25: 142-149.
36. Huang RS, Gamazon ER, Ziliak D, Wen Y, Im HK, Zhang W, Wing C, Duan S, Bleibel WK, Cox NJ, Dolan ME. Population differences in miRNA expression and biological implications. RNA Biol 2011; 8: 692-701.
37. Boeckel JN, ThomeCE, Leistner D, Zeiher AM, Fichtlscherer S, Dimmeler S. Heparin selectively affects the quantification of MicroRNAs in human blood samples. Clin Chem 2013; 59: 1125-1127.